Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared OncoDailyBreast’s post on X, adding:
“Appreciate the prospective data to show that ADC sequencing with the same payload has limited efficacy. This data is consistent with Clinical Cancer Research preclinical data.
This is why we need new strategy to overcome the ADC resistance. New payload, new target, new combination, etc.”
Title: Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Authors: Dileep Reddy Rampa, Minji Seo, Nanae Ogata, Zhaoxuan Yang, Nithya Sridhar, Takeo Fujii, Chalothorn Wannaphut, Jennifer A. Maynard, Kyoji Tsuchikama, George W. Sledge, Jr, Naoto T. Ueno, Jangsoon Lee
Quoting OncoDailyBreast‘s post:
“ESMO Breast 2026: SATEEN Trial Reports Limited Activity of SG Plus Trastuzumab After T-DXd
The phase II SATEEN trial evaluated sacituzumab govitecan plus trastuzumab in heavily pretreated HER2+ metastatic breast cancer after prior trastuzumab deruxtecan.
Presented by Paolo Tarantino at ESMO Breast 2026, the study did not meet its primary endpoint:
- ORR: 3.7%
- 18-week CBR: 14.8%
- Median PFS: 2.3 months
- Median OS: 9.2 months
The findings provide prospective evidence that sequential TOPO1 inhibitor-based ADC strategies may have limited benefit after prior T-DXd in HER2+ metastatic breast cancer.”
Other articles featuring Naoto T Ueno and OncoDailyBreast on OncoDaily.